Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
SEATTLE, March 14, 2017 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C., April 1-5, 2017.
Based on Aptevo’s proprietary ADAPTIR™ protein therapeutic platform, the Company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies. Results being presented at AACR will examine the in vitro and in vivo activity of optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia (AML).
| Title: | Bispecific anti-CD123 x anti-CD3 ADAPTIR Molecules for Redirected T-cell Cytotoxicity in Hematological Malignancies |
| Date/Time: | April 2, 2017 – 1:00 – 5:00 pm ET |
| Session Title: | T-Cell Immunity to Cancer – New Progress (Immunology) |
| Abstract ID: | 597/1 |
Abstracts for the AACR annual meeting are available and can be viewed online at www.aacr.org. Aptevo’s poster presentation will be available on the Investor Relations section of the Company’s website at www.aptevotherapeutics.com following the poster session.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source: Aptevo Therapeutics Stacey Jurchison Senior Director, Investor Relations and Corporate Communications 206-859-6628 [email protected]
